The adjuvant treatment of kidney cancer: a multidisciplinary outlook

[1]  Dennis Andersson,et al.  Ensuring trust in COVID-19 data , 2021, Medicine.

[2]  Thomas Gaillat.  A Multifactorial analysis of this, that , 2019, Cahiers de praxématique.

[3]  M. P. Laguna.  Re: Axitinib versus Placebo as an Adjuvant Treatment of Renal Cell Carcinoma: Results from the Phase III, Randomized ATLAS Trial. , 2019, The Journal of urology.

[4]  M. Casey,et al.  Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  R. Motzer,et al.  JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  C. Porta,et al.  Opening an onconephrology clinic: recommendations and basic requirements , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[8]  A. Ravaud,et al.  IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC) , 2018 .

[9]  R. Montironi,et al.  Editorial on “Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial” , 2018 .

[10]  R. Motzer,et al.  Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma , 2018, Clinical Cancer Research.

[11]  C. Porta,et al.  Adjuvant therapy in renal cell carcinoma. , 2017, Cancer treatment reviews.

[12]  R. Motzer,et al.  Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Manola,et al.  Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial , 2017, JAMA oncology.

[14]  C. Supuran.  Carbonic Anhydrase Inhibition and the Management of Hypoxic Tumors , 2017, Metabolites.

[15]  A. Belldegrun,et al.  Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial , 2017, JAMA oncology.

[16]  H. Jang,et al.  The role of targeted agents in the adjuvant treatment of colon cancer: a meta-analysis of randomized phase III studies and review , 2017, Oncotarget.

[17]  C. Porta,et al.  Pharmacotherapy for treating metastatic clear cell renal cell carcinoma , 2017, Expert opinion on pharmacotherapy.

[18]  M. Smyth,et al.  Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease , 2016 .

[19]  V. Grünwald,et al.  Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. , 2016, Cancer treatment reviews.

[20]  J. Patard,et al.  Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. , 2016, The New England journal of medicine.

[21]  J. Manola,et al.  Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial , 2016, The Lancet.

[22]  P. Russo,et al.  Factors Associated with Recovery of Renal Function following Radical Nephrectomy for Kidney Neoplasms. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[23]  C. Porta,et al.  Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[25]  J. Sabourin,et al.  Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma , 2015, Anti-cancer drugs.

[26]  Margarita Lopatin,et al.  A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. , 2015, The Lancet. Oncology.

[27]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[28]  R. Labianca,et al.  Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-&agr; (IFN-&agr;) in Operable Renal Cell Carcinoma (RCC): A Phase III, Randomized, Multicentre Trial of the Italian Oncology Group for Clinical Research (GOIRC) , 2014, Journal of immunotherapy.

[29]  S. Pal,et al.  Adjuvant therapy for renal cell carcinoma: past, present, and future. , 2014, The oncologist.

[30]  C. Muo,et al.  Increased Risk of End-Stage Renal Disease in Patients with Renal Cell Carcinoma: A 12-Year Nationwide Follow-Up Study , 2014, Medicine.

[31]  M. Kattan,et al.  ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. , 2014, European urology.

[32]  Andrew T. Taylor.  Radionuclides in Nephrourology, Part 2: Pitfalls and Diagnostic Applications , 2014, The Journal of Nuclear Medicine.

[33]  Connie M. Rhee,et al.  Risk of chronic kidney disease after cancer nephrectomy , 2014, Nature Reviews Nephrology.

[34]  A. Reynolds,et al.  Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions , 2014, Angiogenesis.

[35]  C. Porta,et al.  Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. , 2013, Clinical genitourinary cancer.

[36]  P. Kapur,et al.  Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. , 2013, The Lancet. Oncology.

[37]  W. Kaelin,et al.  The VHL/HIF axis in clear cell renal carcinoma. , 2013, Seminars in cancer biology.

[38]  B. Humphreys,et al.  Onco-nephrology: AKI in the cancer patient. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[39]  H. Lee,et al.  Post-operative acute kidney injury in patients with renal cell carcinoma is a potent risk factor for new-onset chronic kidney disease after radical nephrectomy. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[40]  B. Delahunt,et al.  Handling and reporting of nephrectomy specimens for adult renal tumours: a survey by the European Network of Uropathology , 2011, Journal of Clinical Pathology.

[41]  E. Heath,et al.  Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction , 2011, Anti-cancer drugs.

[42]  J. McKiernan,et al.  Predicting renal functional outcomes after surgery for renal cortical tumours: a multifactorial analysis , 2010, BJU international.

[43]  P. Tan,et al.  Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma. , 2010, Urology.

[44]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  A. Renshaw,et al.  Protocol for the examination of specimens from patients with invasive carcinoma of renal tubular origin. , 2010, Archives of pathology & laboratory medicine.

[46]  Gyan Bhanot,et al.  Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. , 2010, Genes & cancer.

[47]  J. W. Lee,et al.  Prognostic factors for chronic kidney disease after curative surgery in patients with small renal tumors. , 2009, Urology.

[48]  V. Margulis,et al.  Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. , 2009, Urology.

[49]  R. Figlin,et al.  An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial , 2008, The Lancet.

[50]  C. Charbonneau,et al.  Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. , 2008, Cancer treatment reviews.

[51]  J. Patard,et al.  Multi-institutional validation of a new renal cancer-specific survival nomogram. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Andrew J Vickers,et al.  Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. , 2006, The Lancet. Oncology.

[53]  M. Gruber,et al.  Hypoxia-inducible factors, hypoxia, and tumor angiogenesis , 2006, Current opinion in hematology.

[54]  P. Fornara,et al.  Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) , 2005, British Journal of Cancer.

[55]  J. Lam,et al.  Surveillance following radical or partial nephrectomy for renal cell carcinoma , 2005, Current urology reports.

[56]  W. Lehmacher,et al.  Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial , 2004, The Lancet.

[57]  R. Figlin,et al.  Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  J. Manola,et al.  Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  J. Cheville,et al.  Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma , 2003, Cancer.

[60]  J. Cheville,et al.  An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. , 2002, The Journal of urology.

[61]  M. Kattan,et al.  A postoperative prognostic nomogram for renal cell carcinoma. , 2001, The Journal of urology.

[62]  R. Figlin,et al.  Improved prognostication of renal cell carcinoma using an integrated staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  P. Boracchi,et al.  Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  S. Naito,et al.  Postoperative UFT Adjuvant and the Risk Factors for Recurrence in Renal Cell Carcinoma: A Long‐Term Follow‐Up Study , 1997, International journal of urology : official journal of the Japanese Urological Association.

[65]  R. Talamini,et al.  Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and Bacillus Calmette‐Guèrin: Five‐year results of a prospective randomized study , 1996, Cancer.

[66]  J. Herman,et al.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[67]  Y Kubota,et al.  Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. , 1994, Cancer research.

[68]  J. Brooks,et al.  Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.

[69]  C. Servadio,et al.  Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormono-immuno-versus hormonotherapy. Preliminary report of immunological and clinical aspects. , 1987, Journal of biological response modifiers.

[70]  L. Piva,et al.  Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. , 1987, The Journal of urology.

[71]  C. Porta,et al.  Acute Kidney Injury in Cancer Patients. , 2018, Contributions to nephrology.

[72]  Martyn Shuttleworth,et al.  What is a NOT a Literature Review ? , 2018 .

[73]  K. Bensalah,et al.  European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma , 2016 .

[74]  M. Štimpfel,et al.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 , 2016 .

[75]  Connie M. Rhee,et al.  Risk of chronic kidney disease after cancer , 2014 .

[76]  R. Sylvester,et al.  Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer , 2014, European journal of cancer.

[77]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[78]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.

[79]  J. Epstein,et al.  A long-term follow-up study , 1997 .

[80]  P. Iversen,et al.  A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. , 1987, Scandinavian journal of urology and nephrology.